Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aspen Aerogels (ASPN) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Aspen Aerogels (ASPN) over the last 12 years, with Q3 2025 value amounting to $21000.0.

  • Aspen Aerogels' Change in Accured Expenses rose 10110.29% to $21000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.7 million, marking a year-over-year decrease of 40624.71%. This contributed to the annual value of -$14.1 million for FY2024, which is 7127.91% down from last year.
  • As of Q3 2025, Aspen Aerogels' Change in Accured Expenses stood at $21000.0, which was up 10110.29% from -$1.1 million recorded in Q2 2025.
  • Over the past 5 years, Aspen Aerogels' Change in Accured Expenses peaked at $22.7 million during Q3 2022, and registered a low of -$19.8 million during Q1 2025.
  • In the last 5 years, Aspen Aerogels' Change in Accured Expenses had a median value of $21000.0 in 2025 and averaged -$223578.9.
  • In the last 5 years, Aspen Aerogels' Change in Accured Expenses surged by 2620909.09% in 2021 and then plummeted by 92023.35% in 2022.
  • Quarter analysis of 5 years shows Aspen Aerogels' Change in Accured Expenses stood at $1.0 million in 2021, then tumbled by 920.23% to -$8.4 million in 2022, then soared by 206.45% to $9.0 million in 2023, then tumbled by 109.0% to -$808000.0 in 2024, then surged by 102.6% to $21000.0 in 2025.
  • Its Change in Accured Expenses was $21000.0 in Q3 2025, compared to -$1.1 million in Q2 2025 and -$19.8 million in Q1 2025.